Company

Renovacor

Biotechnology Research The Monogenic Cause of This Severe Form of Heart Failure. Renovacor’s Vision Is to Bring Life-changing Therapies to Patients Living with Serious Genetic Cardiovascular and Related Diseases 7 employees

Employees: 7
Contacts: 1
Emails: 1
Phones: 1

renovacor.com LinkedIn Crunchbase

Renovacor Overview

Headquarters: The Monogenic Cause of This Severe Form of Heart Failure. Renovacor’s Vision Is to Bring Life-changing Therapies to Patients Living with Serious Genetic Cardiovascular and Related Diseases
Website: renovacor.com
Industry: Biotechnology Research
Employees: 7
Founded: 2019
Funding: 30.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Cardiology and Gene Therapy

About Renovacor

Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.